Cargando…
Cancer screening in China: a steep road from evidence to implementation
Cancer screening has the potential to decrease mortality from several common cancer types. The first cancer screening programme in China was initiated in 1958 and the Cancer High Incidence Fields established in the 1970s have provided an extensive source of information for national cancer screening...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665203/ https://www.ncbi.nlm.nih.gov/pubmed/38000379 http://dx.doi.org/10.1016/S2468-2667(23)00186-X |
_version_ | 1785148837302632448 |
---|---|
author | Xia, Changfa Basu, Partha Kramer, Barnett S Li, He Qu, Chunfeng Yu, Xue Qin Canfell, Karen Qiao, Youlin Armstrong, Bruce K Chen, Wanqing |
author_facet | Xia, Changfa Basu, Partha Kramer, Barnett S Li, He Qu, Chunfeng Yu, Xue Qin Canfell, Karen Qiao, Youlin Armstrong, Bruce K Chen, Wanqing |
author_sort | Xia, Changfa |
collection | PubMed |
description | Cancer screening has the potential to decrease mortality from several common cancer types. The first cancer screening programme in China was initiated in 1958 and the Cancer High Incidence Fields established in the 1970s have provided an extensive source of information for national cancer screening programmes. From 2012 onwards, four ongoing national cancer screening programmes have targeted eight cancer types: cervical, breast, colorectal, lung, oesophageal, stomach, liver, and nasopharyngeal cancers. By synthesising evidence from pilot screening programmes and population-based studies for various screening tests, China has developed a series of cancer screening guidelines. Nevertheless, challenges remain for the implementation of a fully successful population-based programme. The aim of this Review is to highlight the key milestones and the current status of cancer screening in China, describe what has been achieved to date, and identify the barriers in transitioning from evidence to implementation. We also make a set of implementation recommendations on the basis of the Chinese experience, which might be useful in the establishment of cancer screening programmes in other countries. |
format | Online Article Text |
id | pubmed-10665203 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-106652032023-11-21 Cancer screening in China: a steep road from evidence to implementation Xia, Changfa Basu, Partha Kramer, Barnett S Li, He Qu, Chunfeng Yu, Xue Qin Canfell, Karen Qiao, Youlin Armstrong, Bruce K Chen, Wanqing Lancet Public Health Review Cancer screening has the potential to decrease mortality from several common cancer types. The first cancer screening programme in China was initiated in 1958 and the Cancer High Incidence Fields established in the 1970s have provided an extensive source of information for national cancer screening programmes. From 2012 onwards, four ongoing national cancer screening programmes have targeted eight cancer types: cervical, breast, colorectal, lung, oesophageal, stomach, liver, and nasopharyngeal cancers. By synthesising evidence from pilot screening programmes and population-based studies for various screening tests, China has developed a series of cancer screening guidelines. Nevertheless, challenges remain for the implementation of a fully successful population-based programme. The aim of this Review is to highlight the key milestones and the current status of cancer screening in China, describe what has been achieved to date, and identify the barriers in transitioning from evidence to implementation. We also make a set of implementation recommendations on the basis of the Chinese experience, which might be useful in the establishment of cancer screening programmes in other countries. Elsevier, Ltd 2023-11-21 /pmc/articles/PMC10665203/ /pubmed/38000379 http://dx.doi.org/10.1016/S2468-2667(23)00186-X Text en © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Xia, Changfa Basu, Partha Kramer, Barnett S Li, He Qu, Chunfeng Yu, Xue Qin Canfell, Karen Qiao, Youlin Armstrong, Bruce K Chen, Wanqing Cancer screening in China: a steep road from evidence to implementation |
title | Cancer screening in China: a steep road from evidence to implementation |
title_full | Cancer screening in China: a steep road from evidence to implementation |
title_fullStr | Cancer screening in China: a steep road from evidence to implementation |
title_full_unstemmed | Cancer screening in China: a steep road from evidence to implementation |
title_short | Cancer screening in China: a steep road from evidence to implementation |
title_sort | cancer screening in china: a steep road from evidence to implementation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665203/ https://www.ncbi.nlm.nih.gov/pubmed/38000379 http://dx.doi.org/10.1016/S2468-2667(23)00186-X |
work_keys_str_mv | AT xiachangfa cancerscreeninginchinaasteeproadfromevidencetoimplementation AT basupartha cancerscreeninginchinaasteeproadfromevidencetoimplementation AT kramerbarnetts cancerscreeninginchinaasteeproadfromevidencetoimplementation AT lihe cancerscreeninginchinaasteeproadfromevidencetoimplementation AT quchunfeng cancerscreeninginchinaasteeproadfromevidencetoimplementation AT yuxueqin cancerscreeninginchinaasteeproadfromevidencetoimplementation AT canfellkaren cancerscreeninginchinaasteeproadfromevidencetoimplementation AT qiaoyoulin cancerscreeninginchinaasteeproadfromevidencetoimplementation AT armstrongbrucek cancerscreeninginchinaasteeproadfromevidencetoimplementation AT chenwanqing cancerscreeninginchinaasteeproadfromevidencetoimplementation |